Clinical Trial Update: Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial comparing GDC-0941 or GDC-0980 in combination with Fulvestrant versus Fulvestrant alone in advanced or metastatic breast cancer that is resistant …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• GDC-0941 (GDC-0941)
• GDC-0980

Snippet

Sponsor: Genentech, Inc. | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED